Business
Ehave and MedReleaf Enter Partnership to Optimize the Therapeutic Potential of Medical Cannabis Products
Ehave and MedReleaf Enter Partnership to Optimize the Therapeutic Potential of Medical Cannabis Products.
About this update from Ehave Inc.
[{"type":"text","content":"\n\n\n\nEhave and MedReleaf Enter Partnership to Optimize the Therapeutic Potential of Medical Cannabis Products\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nEhave and MedReleaf Enter Partnership to Optimize the Therapeutic Potential of Medical Cannabis Products\nCanada NewsWire\nTORONTO, Feb. 14, 2017\n\n\n\n \nNovel mental health informatics technology offers precision to medical cannabis industry\n\n\n\nTORONTO, Feb. 14, 2017 /CNW/ -- Ehave, Inc. (OTCQB:EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, and MedReleaf Corp., Canada's premium medical cannabis licensed producer, today announced that the companies have entered into a partnership to develop a branded MedReleaf app utilizing the Ehave Connect mental health informatics platform to advance the study and therapeutic use of medical cannabis.  Ehave Connect enables developers, and ultimately prescribers, of medical cannabis to design and monitor treatment plans, track patient compliance, and verify treatment outcomes in a reliable and objective manner.\n\nTogether, Ehave and MedReleaf seek to validate and optimize the use of MedReleaf's medical cannabis products as therapeutic treatments for various mental health conditions. Initially, the companies will use Ehave Connect to manage treatment plans and track patient outcomes as part of a clinical trial to evaluate medical cannabis's potential ability to provide relief to persons suffering from post-traumatic stress disorder (\"PTSD\").  Ultimately, it is anticipated that the MedReleaf App based on the Ehave Connect platform can be used to monitor every step of the medical cannabis treatment life cycle, from diagnosis and treatment planning to medication adherence and outcomes verification.\n\nValidating therapeutic dosing and administration of cannabis-based therapies, while paramount to developing new products and promoting clinical acceptance, remains a challenge, particularly in mental health indications where patient outcomes are difficult to track. Currently, th...